Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Severe COVID-19 Pneumonia (Denmark Phase 2)
2020-001154-22Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia, viral pneumonia and coronavirus disease 2019 (COVID-19) comparing Tocilizumab arm with Placebo arm (2 arms). Primary endpoint: Clinical status on 7-category ordinal scale. Started Mar 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus pneumoniaviral pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001154-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001154-22.